...
首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities-Report from an ECVAM workshop.
【24h】

Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities-Report from an ECVAM workshop.

机译:减少在遗传毒性测试中的动物使用:确定和实施的机会-ECVAM研讨会的报告。

获取原文
获取原文并翻译 | 示例
           

摘要

In vivo genetic toxicology tests measure direct DNA damage or the formation of gene or chromosomal mutations, and are used to predict the mutagenic and carcinogenic potential of compounds for regulatory purposes and/or to follow-up positive results from in vitro testing. These tests are widely used and consume large numbers of animals, with a foreseeable marked increase as a result of the EU chemicals legislation (REACH), which may require follow-up of any positive outcome in the in vitro standard battery with appropriate in vivo tests, regardless of the tonnage level of the chemical. A 2-day workshop with genotoxicity experts from academia, regulatory agencies and industry was hosted by the European Centre for the Validation of Alternative Methods (ECVAM) in Ranco, Italy from 24 to 25 June 2008. The objectives of the workshop were to discuss how to reduce the number of animals in standard genotoxicity tests, whether the application of smarter test strategies can lead to lower animal numbers, and how the possibilities for reduction can be promoted and implemented. The workshop agreed that there are many reduction options available that are scientifically credible and therefore ready for use. Most of these are compliant with regulatory guidelines, i.e. the use of one sex only, one administration and two sampling times versus two or three administrations and one sampling time for micronucleus (MN), chromosomal aberration (CA) and Comet assays; and the integration of the MN endpoint into repeat-dose toxicity studies. The omission of a concurrent positive control in routine CA and MN tests has been proven to be scientifically acceptable, although the OECD guidelines still require this; also the combination of acute MN and Comet assay studies are compliant with guidelines, except for sampling times. Based on the data presented at the workshop, the participants concluded that these options have not been sufficiently utilized to date. Key factors for this seem to be the uncertainty regarding regulatory compliance/acceptance, lack of awareness, and an in many cases unjustified uncertainty regarding the scientific acceptance of reduction options. The workshop therefore encourages the use and promotion of these options as well as the dissemination of data related to reduction opportunities by the scientific community in order to boost the acceptance level of these approaches. Furthermore, experimental proof is needed and under way to demonstrate the credibility of additional options for reduction of the number of animals, such as the integration of the Comet assay into repeat-dose toxicity studies.
机译:体内遗传毒理学测试可测量直接的DNA损伤或基因或染色体突变的形成,并用于预测化合物的致突变和致癌潜力,以用于调节目的和/或跟踪体外测试的阳性结果。这些测试被广泛使用并消耗大量动物,并且由于欧盟化学品法规(REACH)的可预见的显着增加,可能需要通过适当的体内测试对体外标准电池中任何阳性结果进行随访,而不考虑化学品的吨位。欧洲替代验证方法中心(ECVAM)于2008年6月24日至25日在意大利兰科举办了为期2天的研讨会,由来自学术界,监管机构和行业的遗传毒性专家主持。该研讨会的目的是讨论如何为了减少标准遗传毒性测试中的动物数量,采用更智能的测试策略是否可以减少动物数量,以及如何推广和实施减少动物数量的方法。讲习班同意,有许多减少选项可供选择,这些选项在科学上是可信的,因此可以立即使用。其中大多数符合监管准则,即使用微性别(MN),染色体畸变(CA)和彗星试验仅使用一种性别,一次给药和两次采样时间对比两次或三次给药和一次或两次采样时间;并将MN终点纳入重复剂量毒性研究中。在常规的CA和MN测试中,省略同时的阳性对照已被证明是科学上可以接受的,尽管OECD指南仍然要求这样做。除采样时间外,急性MN和Comet分析研究的组合均符合指南。根据讲习班上提供的数据,与会人员得出的结论是,迄今为止这些选择尚未得到充分利用。造成这种情况的关键因素似乎是监管合规性/接受性的不确定性,缺乏意识以及在许多情况下科学地接受减排方案的不合理不确定性。因此,讲习班鼓励使用和推广这些选择,并鼓励科学界传播与减少机会有关的数据,以提高对这些方法的接受程度。此外,需要实验证据并正在进行实验以证明减少动物数量的其他选择的可信度,例如将Comet分析整合到重复剂量毒性研究中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号